AD01 Follow up Extension Visit

Follow-up Study to Assess Safety and Clinical Activity of Continued AFFITOPE® AD02 Vaccinations of Patients Who Participated in AFF006

NCT02008513 ·Status: TERMINATED ·Phase: PHASE2

Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease

NCT01117818 ·Status: COMPLETED ·Phase: PHASE2

Tolerability and Safety of Subcutaneous Administration of Affitope AD01 in Mild to Moderate Alzheimer's Disease

NCT00495417 ·Status: COMPLETED ·Phase: PHASE1

Tolerability and Safety of Subcutaneous Administration of AFFITOPE AD02 in Mild to Moderate Alzheimer's Disease

NCT00633841 ·Status: COMPLETED ·Phase: PHASE1

Safety and Tolerability of AFFITOPE AD03

NCT01309763 ·Status: COMPLETED ·Phase: PHASE1

A Study to Evaluate the Long-term Safety and Tolerability of Lu AF20513 and the Antibody Response in Patients With Alzheimer's Disease (AD)

NCT03668405 ·Status: TERMINATED ·Phase: PHASE1

Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease

NCT01238991 ·Status: TERMINATED ·Phase: PHASE2

Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease

NCT01850238 ·Status: COMPLETED ·Phase: PHASE1

A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease

NCT05744401 ·Status: TERMINATED ·Phase: PHASE2

Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

NCT01690195 ·Status: TERMINATED ·Phase: PHASE2

Study With Lu AF20513 in Patients With Mild Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI) Due to AD

NCT03819699 ·Status: TERMINATED ·Phase: PHASE1

A Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of ABT-126 in Subjects With Alzheimer's Disease

NCT01482845 ·Status: COMPLETED ·Phase: PHASE1

Open-Label Extension Protocol to SNK01-AD01 Study

NCT07228078 ·Status: RECRUITING ·Phase: PHASE2

A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer's Disease

NCT04445831 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

NCT00955409 ·Status: COMPLETED ·Phase: PHASE2

12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension

NCT02586909 ·Status: TERMINATED ·Phase: PHASE3

Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

NCT06304883 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease

NCT00948909 ·Status: COMPLETED ·Phase: PHASE2

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

NCT01549834 ·Status: COMPLETED ·Phase: PHASE2

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

NCT01676935 ·Status: TERMINATED ·Phase: PHASE2

A Safety and Tolerability Study of ABT-126 in Elderly

NCT00867399 ·Status: COMPLETED ·Phase: PHASE1

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

NCT01369225 ·Status: COMPLETED ·Phase: PHASE1

Open-Label Extension Study of 23 mg Donepezil SR in Participants With Moderate to Severe Alzheimer's Disease

NCT00566501 ·Status: COMPLETED ·Phase: PHASE3

An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Disease in the US

NCT05097131 ·Status: TERMINATED

Follow-up Study of the Alzheimer's Disease Anti-Inflammatory Prevention Trial

NCT01417130 ·Status: UNKNOWN